Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Share-based Compensation (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Share-based Compensation for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 1.85% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 2.83% year-over-year, with the annual reading at $7.6 million for FY2025, 2.81% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.5 million at Mereo BioPharma, down from $1.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $2.3 million in Q1 2025, with the low at $815000.0 in Q4 2023.
  • Average Share-based Compensation over 3 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 121.42% in 2024, then fell 1.38% in 2025.
  • Over 3 years, Share-based Compensation stood at $815000.0 in 2023, then surged by 85.89% to $1.5 million in 2024, then rose by 1.85% to $1.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $1.5 million, $1.7 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.